individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

- **Name of Committee:** Arthritis and Musculoskeletal and Skin Diseases Initial Review Group; Arthritis and Musculoskeletal and Skin Diseases Clinical Trials Review Committee.

  **Date:** October 24, 2017.
  **Time:** 8:00 a.m. to 5:00 p.m.
  **Agenda:** To review and evaluate grant applications.

  **Place:** Bethesda North Marriott, 5701 Marinelli Road, Rockville, MD 20852.

  **Contact Person:** Kathy Salaita, SCD, Chief, Scientific Review Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, DHHS/National Institutes of Health, 6701 Democracy Boulevard, Room 818, Bethesda, MD 20892, 301–594–5033 (office), 301–402–2406 (fax), Kathy.Salaita@nih.gov.

- **Name of Committee:** National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; AMSIC Conflict Review Meeting.

  **Date:** October 26, 2017.
  **Time:** 11:00 a.m. to 1:30 p.m.
  **Agenda:** To review and evaluate grant applications.

  **Place:** National Institute of Arthritis and Musculoskeletal and Skin Diseases, 6701 Democracy Boulevard, Suite 816, Bethesda, MD 20892 (Teleconference).

  **Contact Person:** Nakia C. Brown, Ph.D., Scientific Review Officer, 6701 Democracy Boulevard, Room 816, Bethesda, MD 20892, 301–827–4905, brownnac@mail.nih.gov.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Center for Scientific Review Special Emphasis Panel; PAR Panel.